Cellectis -ASH 2021 Abstracts TALEN® for Best-In-Class Gene Editing Cellectis leverages its leadership in gene editing through its flagship technology, TALEN®, which allows the company to create CAR T therapies to bring new hope to cancer patients through broadly available, off-the-shelf therapies. TALEN® has been successfully used in the clinic to solve key challenges with allogeneic CAR T including protection from Graft vs. Host Disease, mitigation of rejection and enhanced safety via the integration of a suicide switch. LEARN MORE "Off-the-shelf" immunotherapies that can work for the largest number of patients Cellectis gene-edits “Chimeric Antigen Receptor” (CAR) T-cells from healthy donors into “off-the-shelf” immunotherapy product candidates that are designed to work for the largest number of patients. It’s the difference between being an off-the-shelf product and a service in which each treatment has to be custom-made. This same technology, developed by Cellectis, could help in designing therapies for many other diseases. LEARN MORE Strong intellectual property, global strategic partnerships. 21 years of innovation. 138 patent families. 107 granted patents and 568 applications. Global strategic partnerships with Allogene, Servier, Iovance, and leading universities all over the world. LEARN MORE Editing Life PRESS Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer Published on: November 11, 2021, 17:19 E.S.T. Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT Published on: October 28, 2021, 11:08 E.S.T. Cellectis Announces Participation in Five Investor Conferences Published on: August 26, 2021, 14:38 E.S.T. Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021 Published on: August 05, 2021, 14:43 E.S.T. Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities Published on: June 14, 2021, 14:11 E.S.T. Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T Published on: May 11, 2021, 13:05 E.S.T. Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021 Published on: May 06, 2021, 14:28 E.S.T. Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021 Published on: April 26, 2021, 15:06 E.S.T. Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq Published on: March 29, 2021, 14:48 E.S.T. Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results Published on: March 04, 2021, 14:59 E.S.T. Cellectis to Hold Fourth Quarter 2020 Earnings Call on Friday, March 5, 2021 at 8:00AM EST Published on: February 25, 2021, 15:29 E.S.T. Cytovia Therapeutics and Cellectis Partner to Develop TALEN® Gene-Edited iPSC-Derived Natural Killer Cells Published on: February 16, 2021, 01:00 E.S.T. Cellectis Announces Launch of Follow-On Offering Published on: December 14, 2020, 15:48 E.S.T. Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting Published on: December 05, 2020, 17:00 E.S.T. FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma Published on: November 17, 2020, 18:58 E.S.T. Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer November 12, 2021 – New York – Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage gene-editing company employing its core technology to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor (CAR-)T cells in the field of immuno-oncology and gene-edited hematopoietic stem cells in other indications, announced the first preclinical data on UCARTMESO, its allogeneic CAR-T cell product candidate targeting mesothelin, being developed for patients with mesothelin-expressing solid tumors. READ MORE ALL PRESS RELEASES LEGAL NOTICEGLOSSARYMEDIA LIBRARYCONTACTCOMMUNITY GUIDELINES Subsidiary: Calyxt Inc.